(Press-News.org) Rockville, MD – July 18, 2024
The National Foundation for Cancer Research (NFCR) announced new Board of Directors members today who both have been long-term supporters of the organization: Silas Deane, Vice President, Tyler Technologies, and Dr. Padmakumar Kaimal, previous Vice President of Technology Alliance & Business Development at Suven Life Sciences. The areas of expertise and leadership they bring to NFCR signify a pivotal moment for the organization working to advance the mission of providing new areas of hope and solutions for cancer patients worldwide.
Silas Deane has extended expertise in technology, healthcare, government relations, and communications. His diverse career path includes working with U.S. Senator and Vice President Al Gore, Jr., and leadership roles at Tyler Technologies (NYSE: TYL), VendEngine, Inc., Logic Media Group, and the International Microelectronics Packaging Society.
Deane founded VendEngine, Inc. to assist public safety officials while supporting incarcerated individuals and their families with real-time data and a safe system that improved staff effectiveness and transparency. The company was acquired in 2021 for $84 million by Tyler Technologies, where he currently serves as Vice President, driving new innovation and growth in the public safety arena. Deane, recognized by Deloitte & Touche in 2020 as growing one of the Top 300 Fastest Growing Technology Companies in North America along with numerous awards for his entrepreneurial achievements, will now bring invaluable expertise to one of the most complex problem-solving and sustainable business models as NFCR continues to lead in the fight against cancer.
“As we learn more and more, it is increasingly evident that the fight against cancer is such a complicated one that is going to continue to take tremendous effort and research to win this battle. I am deeply honored to join the Board of Directors at NFCR and believe that continued investment in research is the key to unlocking the mystery. NFCR has already played a huge role in the success against cancer, and I am proud to be a part of that next chapter in the fight,” says Deane.
"Silas's creative mindset and innovative approach to technology and business development make him an exceptional addition to our Board. We look forward to working with him to broaden our brand visibility as we consistently seek out new ways to beat cancer," says Dr. Sujuan Ba, the President and CEO at NFCR.
Dr. Padmakumar Kaimal's academic credentials and industrial experience are exemplary. He has worked in the pharmaceutical and contract manufacturing industries for more than 30 years. Before his retirement, he served as Vice President of Technology Alliance & Business Development at Suven Life Science, successfully expanding the U.S. business from $200,000 in 2003 to $80 million in 2023. Additionally, he has contributed to over 34 scientific publications and holds four patents, highlighting his innovative contributions to the medicinal chemical synthesis field. Dr. Kaimal currently advises biotech and pharmaceutical companies on their CDMO processes, with his extensive knowledge and expertise.
“It is an absolute privilege to be part of advancing the NFCR mission. Throughout my career, I have seen the incredible strides that can be made through dedicated research and collaboration between scientists. Joining NFCR leadership allows me to contribute to a mission that not only aligns with my professional background but also my personal goal of improving patient outcomes and driving forward scientific breakthroughs in cancer research. I look forward to working with the team to advance NFCR's impactful initiatives and make a real difference that will shape the future of cancer research,” says Dr. Kaimal.
"Kumar's impressive background in pharmaceutical process research and business development, combined with his successful track record in growing business at Suven, makes him a great addition to our Board. We look forward to leveraging his knowledge and experience to help advance many of the innovations supported by NFCR," says Dr. Sujuan Ba.
"I am thrilled to welcome Mr. Silas Deane and Dr. Padmakumar Kaimal to our Board of Directors. Their extensive and diverse expertise in business development, technology, science, and healthcare will bring invaluable perspectives to our leadership team. Their unique insights and vast experiences in their respective fields will undoubtedly enhance NFCR's strategic initiatives and accelerate our progress in cancer research and patient care. The addition of Deane and Kaimal strengthens our ability to collaborate across various sectors and drive organizational growth," says Dr. Alfred Slanetz, Chairman of the Board of Directors of NFCR.
We look forward to working with Deane and Dr. Kaimal in their new capacities as the new members of the board driving innovation and expanding our impact on the journey of fighting against cancer.
About NFCR:
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing "high-risk, high-impact" long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.3 million individual donors over the last 50+ years, NFCR has provided more than $415 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today. For more information, please visit www.nfcr.org.
END
NFCR welcomes two new Board of Directors
2024-07-18
ELSE PRESS RELEASES FROM THIS DATE:
In decade-first for Japan, Kyushu U Professor is elected as International Fellow of the British Academy
2024-07-18
Fukuoka, Japan — On 17 July 2024, the British Academy held its Annual General Meeting, where Koji Mizoguchi, Professor of Archaeology at Kyushu University's Faculty of Social and Cultural Studies, was elected as an International Fellow. He is the first Japanese archaeologist and the first researcher from Kyushu University to receive this honor.
Founded in 1902, the British Academy aims to deepen and share understanding of people, societies, and cultures across time and place, enabling ...
PEPITEM – a novel protective agent for inflammageing
2024-07-18
A naturally occurring peptide called PEPITEM could potentially rejuvenate the immune response in older individuals and protect against 'inflammageing', which is widely believed to be the root cause of many age-related diseases.
The study, published today in the journal npj Aging, raises the exciting possibility of a protective agent that could dampen age-related inflammation and restore normal immune function in older adults.
PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) was initially identified at the University ...
Small animals acquire genes from bacteria that can produce antibiotics
2024-07-18
WOODS HOLE, Mass. -- A group of small, freshwater animals protect themselves from infections using antibiotic recipes “stolen” from bacteria, according to new research by a team from the University of Oxford, the University of Stirling and the Marine Biological Laboratory (MBL), Woods Hole.
The tiny creatures are called bdelloid rotifers, which means ‘crawling wheel-animals’. They have a head, mouth, gut, muscles and nerves like other animals, though they are smaller than a hair’s breadth.
When these rotifers are exposed to fungal infection, the study found, ...
Unexpected role of OTX2 drives aggressive medulloblastoma
2024-07-18
In a report published in Nature Cell Biology, researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma – the most common aggressive childhood brain cancer. The findings suggest that targeting OTX2 or its effects can have therapeutic relevance.
“We see medulloblastoma stem cells as the root of the disease. The tumors develop from these cells early during development of the cerebellum, the brain region ...
Study shows new efficiency standards for heavy trucks could boost energy use
2024-07-18
Deliveries are getting faster than ever in the U.S., but the faster movement of goods is undercutting the country’s climate progress.
In a new study published July 18 in the journal Nature Energy, a CU Boulder researcher and his collaborator estimate that federal regulations aimed at enhancing heavy-duty trucks’ energy efficiency could be as much as 20% less effective than policymakers initially anticipated.
That’s because the regulations make trucking cheaper. As a result, more shippers will likely switch from using less energy-intensive rail transportation to using more energy-intensive trucks to ship goods.
“We ...
Minerals play newly discovered role in Earth’s phosphorus cycle
2024-07-18
Northwestern University-led researchers have discovered a new way that nature cycles phosphorus, a finding that uncovers a missing piece of Earth’s puzzling phosphorus cycle.
The research will be published on Thursday (July 18) in the journal Nature Communications.
A critical nutrient for plant growth, phosphorus is a non-negotiable component of fertilizers. Without it, farmers cannot ensure plant health and boost crop yields. Understanding Earth’s phosphorus cycle, therefore, is important for protecting the global food supply.
Although ...
Social media: How algorithms influence election campaigns
2024-07-18
Milano, 18 luglio 2024 – A new study published in the journal PNAS Nexus reveals how social media algorithms favor politically sponsored content from certain parties given the same investment budget.
The research, a collaboration between the Politecnico di Milano, LMU – Ludwig Maximilians Universität of Munich, and the CENTAI institute of Turin, analyzed over 80,000 political ads on Facebook and Instagram before the 2021 German federal elections. These ads were placed by parties across the political spectrum and generated over 1.1 billion impressions during an election with more than 60 million eligible voters.
Investigating ...
IOP Publishing launches series of open access journals dedicated to machine learning and artificial intelligence for the sciences
2024-07-18
IOP Publishing (IOPP) is launching the world’s first series of open access journals dedicated to the application and development of machine learning (ML) and artificial intelligence (AI) for the sciences. The new multidisciplinary Machine Learning series will collectively cover applications of ML and AI across the physical sciences, engineering, biomedicine and health, and environmental and earth science.
Building on the successful launch of Machine Learning: Science and Technology in 2019, IOPP’s Machine Learning series will expand to include three new ...
Research shows young infants use their mother’s scent to see faces
2024-07-18
Humans see the world through the five senses, but how and when the ability to integrate across the senses arises is debated. Research shows that humans combine sensory information together, particularly when one sense is not able to produce a sufficient response alone. Studies also show that infants may use multisensory cues to perceive their environments more efficiently. A new Child Development study by researchers at the Université de Bourgogne, University of Hamburg, Université de Lyon, Institut Universitaire de France, Université de Lorraine, Centre Hospitalier de Nancy, and Centre National de la Recherche Scientifique ...
Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
2024-07-18
Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient’s organ functions. A type of anti-tumor immunotherapy called allogeneic hematopoietic cell transplantation, which can exert anti-cancer effect accompanied by severe toxicity, is often performed for patients who are hard to treat with chemotherapy, but relapse still remains.
The hematopoietic cell transplant team in ...